• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Masimo Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    5/27/25 9:00:17 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MASI alert in real time by email
    masi-20250527
    0000937556false00009375562025-05-272025-05-27

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ________________________________________________
    FORM 8-K
    ________________________________________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 27, 2025
    masimologoq32019b.jpg
    MASIMO CORPORATION
    (Exact name of registrant as specified in its charter)
    ________________________________________________
    DE001-3364233-0368882
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    52 DiscoveryIrvine,CA92618
    (Address of Principal Executive Offices)(Zip Code)
    (949)
    297-7000
    Registrant’s telephone number, including area code:
    Not Applicable
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities Registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par valueMASIThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐




    Item 7.01.Regulation FD Disclosure.
    Management of Masimo Corporation (the “Company”) intends to participate in discussions with investors during the upcoming week at which the Company intends to re-affirm the updated financial outlook for the remainder of fiscal 2025 that it provided on May 6, 2025.
    At the present time, the Company does not expect the cybersecurity-related incident reported under Item 8.01 of Form 8-K on May 6, 2025, which is further updated in Item 8.01 below, to materially impact the Company’s revenue for fiscal year 2025, or to prevent the Company from fulfilling customer orders received to date or meeting seasonal demand.
    The Company maintains cybersecurity insurance, and expects that the majority of out-of-pocket remediation costs incurred by the Company in connection with the incident will be covered by such insurance, and that any such costs will be non-recurring in nature.
    In accordance with General Instructions B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
    Item 8.01.Other Events.
    As previously reported under Item 8.01 of Form 8-K on May 6, 2025, on April 27, 2025, the Company identified unauthorized activity on the Company’s on-premise network and, upon detection, activated its incident response protocols and implemented containment measures. The Company promptly commenced an investigation and has been actively working to assess, mitigate, and remediate the incident with the assistance of third-party cybersecurity professionals. The Company has also notified and coordinated with law enforcement.
    At this time, the Company’s manufacturing operations are running at near full capacity, and the Company’s critical order taking, distribution and shipping systems are fully operational. The Company is continuing to optimize these systems to ensure that any delayed orders are being processed in a timely manner.
    Forward Looking Statements
    This Current Report on Form 8-K contains forward-looking statements within the meaning of the federal securities laws and include, among other things, statements about the impact of this incident on the Company and the ultimate duration and extent of the disruption. All such statements in this report, other than statements of historical fact, are forward-looking statements. Words such as “expect,” “intend,” “will,” “plan,” “anticipate,” “may,” “believe,” “continue,” and similar expressions are intended to identify forward-looking statements. The Company bases its forward-looking statements on information available to it on the date of this report and undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may otherwise be required by law. Actual results and other events could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. Factors that could cause actual results to differ materially from those expressed or implied include the Company’s discovery of additional information related to the incident, legal, reputational, and financial risks resulting from the incident, any potential regulatory inquiries, enforcement actions and/or litigation to which the Company may become subject in connection with the incident, any contract terminations, disputes or loss of business, and other additional costs that may be incurred by the Company in connection with the incident, and the risks set forth in the Company’s Annual Report on Form 10-K for the year ended December 28, 2024, filed with the Securities and Exchange Commission on February 25, 2025, and the subsequent reports that the Company files with the Securities and Exchange Commission from time to time.
    Item 9.01.Financial Statements and Exhibits.
    (d) The following item is filed as an exhibit to the Current Report on Form 8-K.
    Exhibit
     No.
    Description
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, Masimo Corporation has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
    MASIMO CORPORATION
    Date: May 27, 2025By:
    /s/ MICAH YOUNG
    Micah Young
    Executive Vice President & Chief Financial Officer
    (Principal Financial Officer)

    Get the next $MASI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MASI

    DatePrice TargetRatingAnalyst
    11/17/2025Neutral
    BofA Securities
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    4/15/2024$148.00 → $170.00Hold → Buy
    Stifel
    3/25/2024$117.00 → $160.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$107.00 → $121.00Buy → Hold
    Jefferies
    1/3/2024Buy → Hold
    Needham
    More analyst ratings

    $MASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Szyman Catherine M. exercised 11,141 shares at a strike of $132.96 and covered exercise/tax liability with 4,568 shares (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    2/13/26 5:28:49 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Ops & Clinical Research Sampath Anand sold $2,555,570 worth of shares (18,680 units at $136.81) and exercised 30,000 shares at a strike of $37.84, increasing direct ownership by 38% to 40,909 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    1/30/26 8:13:11 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CTIO & EVP of Engineering Ahmed Omar covered exercise/tax liability with 974 shares and exercised 2,474 shares at a strike of $152.43, increasing direct ownership by 85% to 3,268 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    11/17/25 9:41:07 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Masimo

    BofA Securities initiated coverage of Masimo with a rating of Neutral

    11/17/25 9:40:41 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Raymond James reiterated coverage on Masimo with a new price target

    Raymond James reiterated coverage of Masimo with a rating of Outperform and set a new price target of $194.00 from $170.00 previously

    12/27/24 7:29:29 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo upgraded by Raymond James with a new price target

    Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $170.00

    11/6/24 7:17:22 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    SEC Filings

    View All

    SEC Form DFAN14A filed by Masimo Corporation

    DFAN14A - MASIMO CORP (0000937556) (Subject)

    2/17/26 5:10:35 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFA14A filed by Masimo Corporation

    DEFA14A - MASIMO CORP (0000937556) (Filer)

    2/17/26 4:33:46 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFA14A filed by Masimo Corporation

    DEFA14A - MASIMO CORP (0000937556) (Filer)

    2/17/26 4:31:59 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman of the Board Brennan Michelle bought $30,560 worth of shares (200 units at $152.80), increasing direct ownership by 3% to 7,318 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/14/25 4:42:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Jellison William R bought $437,940 worth of shares (3,000 units at $145.98), increasing direct ownership by 168% to 4,790 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/12/25 4:20:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 26

    Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call or the webcast, please use the link below. Upon registering, each participant will be provided with details for the call or webcast. Conference Call Registration Link (Please register to obtain the dial-in number): Masim

    2/12/26 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Leadership Updates

    Live Leadership Updates

    View All

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Clairity Appoints Founder Dr. Connie Lehman as Chief Executive Officer; Joe Kiani Named Chairman of the Board

    BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors. These leadership appointments reflect a pivotal moment for Clairity following FDA De Novo authorization of its mammography-based AI risk prediction platform and increasing engagement with health systems and partners worldwide. Clairity's innovation aligns with national priorities to improve health o

    1/21/26 4:30:00 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo to Host Investor Day on December 3, 2025

    Masimo (NASDAQ:MASI) today announced it will host a meeting with the analyst and investor community at 9:00am PT on Wednesday, December 3, 2025. Presentations will be led by select members of the Executive Leadership Team and will cover an overview of the company's business, market opportunities, innovation pipeline, commercial growth strategy, and long-term financial outlook. The company invites investors to join the event via live webcast, which will be available on the Investor Relations section of its website at https://investor.masimo.com/ under "Events and Presentations" or directly by visiting the following link: Masimo Investor Day webcast. A replay of the webcast and the relate

    10/9/25 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    9/25/24 4:01:23 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    8/30/24 4:56:53 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    7/17/24 5:29:36 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    Financials

    Live finance-specific insights

    View All

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 26

    Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call or the webcast, please use the link below. Upon registering, each participant will be provided with details for the call or webcast. Conference Call Registration Link (Please register to obtain the dial-in number): Masim

    2/12/26 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Announces Select Preliminary 2025 Financial Results

    Complete fourth quarter and full-year 2025 financial results will be announced on Thursday, February 26, 2026 Masimo Corporation (NASDAQ:MASI) today announced select preliminary financial results for the fourth quarter and full-year ended January 3, 2026. Preliminary Fourth Quarter 2025 Financial Results:   •   Revenue is expected to be approximately $411 million, representing approximately 12% growth on a reported basis and 11% growth on a constant currency basis(1);   •   Non-GAAP earnings per diluted share(2), including the impact of new tariffs, are expected to be more than $1.54; and   •   Shipments of noninv

    1/12/26 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care